JP6678685B2 - 尿酸性または痛風性疾患の予防または治療 - Google Patents
尿酸性または痛風性疾患の予防または治療 Download PDFInfo
- Publication number
- JP6678685B2 JP6678685B2 JP2017558605A JP2017558605A JP6678685B2 JP 6678685 B2 JP6678685 B2 JP 6678685B2 JP 2017558605 A JP2017558605 A JP 2017558605A JP 2017558605 A JP2017558605 A JP 2017558605A JP 6678685 B2 JP6678685 B2 JP 6678685B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- uric acid
- purine
- dione
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WTUVPERXQXSPFE-UHFFFAOYSA-N CCCCCN(c1c(C(N2)=O)[n](CC=C)c(Cl)n1)C2=O Chemical compound CCCCCN(c1c(C(N2)=O)[n](CC=C)c(Cl)n1)C2=O WTUVPERXQXSPFE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510048096 | 2015-01-30 | ||
| CN201510048096.3 | 2015-01-30 | ||
| CN201510080714.2 | 2015-02-13 | ||
| CN201510079809 | 2015-02-13 | ||
| CN201510079809.2 | 2015-02-13 | ||
| CN201510080714 | 2015-02-13 | ||
| CN201510216089.X | 2015-04-30 | ||
| CN201510216089 | 2015-04-30 | ||
| PCT/CN2016/000061 WO2016119570A1 (zh) | 2015-01-30 | 2016-01-28 | 尿酸性或痛风性疾病的预防或治疗 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503691A JP2018503691A (ja) | 2018-02-08 |
| JP2018503691A5 JP2018503691A5 (https=) | 2019-03-07 |
| JP6678685B2 true JP6678685B2 (ja) | 2020-04-08 |
Family
ID=56542370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558605A Active JP6678685B2 (ja) | 2015-01-30 | 2016-01-28 | 尿酸性または痛風性疾患の予防または治療 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10322132B2 (https=) |
| EP (1) | EP3251675B1 (https=) |
| JP (1) | JP6678685B2 (https=) |
| KR (1) | KR102128810B1 (https=) |
| CN (1) | CN107206002B (https=) |
| AU (1) | AU2016212625B2 (https=) |
| BR (1) | BR112017016065A2 (https=) |
| CA (1) | CA2973746C (https=) |
| CY (1) | CY1124383T1 (https=) |
| DK (1) | DK3251675T3 (https=) |
| EA (1) | EA034139B1 (https=) |
| ES (1) | ES2881872T3 (https=) |
| HR (1) | HRP20211007T1 (https=) |
| HU (1) | HUE054741T2 (https=) |
| IL (1) | IL253726B2 (https=) |
| LT (1) | LT3251675T (https=) |
| MA (1) | MA41431B1 (https=) |
| MX (1) | MX380301B (https=) |
| PL (1) | PL3251675T3 (https=) |
| PT (1) | PT3251675T (https=) |
| SG (2) | SG11201705889VA (https=) |
| SI (1) | SI3251675T1 (https=) |
| SM (1) | SMT202100359T1 (https=) |
| TW (1) | TWI680761B (https=) |
| WO (1) | WO2016119570A1 (https=) |
| ZA (1) | ZA201704600B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12566174B2 (en) | 2017-05-11 | 2026-03-03 | The Research Foundation For The State University Of New York | Method and kit for determining the presence of monosodium urate crystals in joint synovial fluid |
| US20260035370A1 (en) | 2023-02-27 | 2026-02-05 | Shanton Pharma Pte. Ltd. | Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor |
| CN116650490B (zh) * | 2023-06-07 | 2025-05-20 | 中国人民解放军海军军医大学 | 化合物mt-1207在降低尿酸方面的应用 |
| EP4497439A1 (en) * | 2023-07-28 | 2025-01-29 | Universitat de les Illes Balears | Compounds for the treatment or prevention of gout |
| TWI902254B (zh) * | 2024-05-16 | 2025-10-21 | 新加坡商珊頓醫藥科技新加坡公司 | 化合物8-氯-3-戊基-3,7-二氫-1h-嘌呤-2,6-二酮的晶型及其製備方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| WO1993016699A1 (en) * | 1992-02-21 | 1993-09-02 | Smithkline Beecham Corporation | Tnf inhibitors |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| CN101103030B (zh) | 2004-02-14 | 2010-10-13 | 史密丝克莱恩比彻姆公司 | 具有hm74a受体活性的药物 |
| CN101479273B (zh) * | 2006-06-23 | 2011-11-30 | 英赛特股份有限公司 | 作为hm74a激动剂的嘌呤酮衍生物 |
| KR20090025262A (ko) * | 2006-06-23 | 2009-03-10 | 인사이트 코포레이션 | Ｈｍ７４ａ 아고니스트로서 푸리논 유도체 |
| WO2010071865A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| US20110136835A1 (en) * | 2009-09-14 | 2011-06-09 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
-
2016
- 2016-01-28 CA CA2973746A patent/CA2973746C/en active Active
- 2016-01-28 KR KR1020177024392A patent/KR102128810B1/ko active Active
- 2016-01-28 SI SI201631264T patent/SI3251675T1/sl unknown
- 2016-01-28 DK DK16742632.9T patent/DK3251675T3/da active
- 2016-01-28 EA EA201791714A patent/EA034139B1/ru unknown
- 2016-01-28 SG SG11201705889VA patent/SG11201705889VA/en unknown
- 2016-01-28 SG SG10201907026RA patent/SG10201907026RA/en unknown
- 2016-01-28 PL PL16742632T patent/PL3251675T3/pl unknown
- 2016-01-28 EP EP16742632.9A patent/EP3251675B1/en active Active
- 2016-01-28 ES ES16742632T patent/ES2881872T3/es active Active
- 2016-01-28 SM SM20210359T patent/SMT202100359T1/it unknown
- 2016-01-28 AU AU2016212625A patent/AU2016212625B2/en active Active
- 2016-01-28 MA MA41431A patent/MA41431B1/fr unknown
- 2016-01-28 HU HUE16742632A patent/HUE054741T2/hu unknown
- 2016-01-28 BR BR112017016065-0A patent/BR112017016065A2/pt not_active Application Discontinuation
- 2016-01-28 LT LTEP16742632.9T patent/LT3251675T/lt unknown
- 2016-01-28 CN CN201680001581.8A patent/CN107206002B/zh active Active
- 2016-01-28 MX MX2017009853A patent/MX380301B/es unknown
- 2016-01-28 JP JP2017558605A patent/JP6678685B2/ja active Active
- 2016-01-28 US US15/512,412 patent/US10322132B2/en active Active
- 2016-01-28 HR HRP20211007TT patent/HRP20211007T1/hr unknown
- 2016-01-28 PT PT167426329T patent/PT3251675T/pt unknown
- 2016-01-28 WO PCT/CN2016/000061 patent/WO2016119570A1/zh not_active Ceased
- 2016-01-29 TW TW105102935A patent/TWI680761B/zh active
-
2017
- 2017-07-07 ZA ZA2017/04600A patent/ZA201704600B/en unknown
- 2017-07-30 IL IL253726A patent/IL253726B2/en unknown
-
2021
- 2021-06-22 CY CY20211100551T patent/CY1124383T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6678685B2 (ja) | 尿酸性または痛風性疾患の予防または治療 | |
| WO2021135654A1 (zh) | 双硫仑在制备防治nlrp3炎症小体相关疾病的药物中的应用 | |
| JP7453251B2 (ja) | アプレミラストおよびｔｙｋ２阻害剤を含む併用療法 | |
| WO2020177744A1 (zh) | 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途 | |
| KR20130097775A (ko) | 테오필린과 페북소스타트의 병용 치료 방법 | |
| JP5302900B2 (ja) | 脂肪性肝疾患の治療用医薬組成物 | |
| JP6511191B2 (ja) | ナフトキノン系化合物を含む、膵炎を治療又は予防する組成物 | |
| JP2022525539A (ja) | 疼痛の治療のためのｇａｂａａ受容体モジュレーターの使用 | |
| EP2762479A1 (en) | Biaryl heterocycle substituted oxazolidinon antibacterial drug | |
| CN111093661A (zh) | 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途 | |
| JP2020502167A (ja) | ピリジン系化合物を有効成分として含有するｄｙｒｋ関連疾患の予防又は治療用薬学的組成物 | |
| CN105272984B (zh) | 吡唑并[3,4-d]嘧啶-4-酮衍生物、其制备方法和应用 | |
| CN105837425B (zh) | (2e, 6e)-2-(3,5-二甲氧基苯基亚甲基)-6-(4-氯苯基亚甲基)环己酮及其衍生物的新应用 | |
| HK1245146B (en) | Prevention or treatment of uric acid or gout disease | |
| HK1244434B (zh) | 尿酸性或痛风性疾病的预防或治疗 | |
| CN106459053B (zh) | 吡唑并[3,4-d]嘧啶-4-酮衍生物、其制备方法和应用 | |
| CN112755192A (zh) | 双环醇类化合物在制备用于预防或治疗动脉粥样硬化疾病的药物中的应用和药物组合物 | |
| WO2025255840A1 (zh) | 治疗患者的中至重度活动性类风湿关节炎的方法 | |
| CN106265677B (zh) | 一种防治溃疡性结肠炎的药物组合物及其应用 | |
| CN121405663A (zh) | 4-氧代噻吩类衍生物及其制备方法和应用 | |
| JP2019182845A (ja) | キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤 | |
| HK40028225A (en) | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines | |
| HK1183638A (en) | Inhibition of inflammation bysimultaneous blockade of multiple prostanoid receptors | |
| HK1183638B (en) | Inhibition of inflammation bysimultaneous blockade of multiple prostanoid receptors | |
| JPH0739423B2 (ja) | ピリミドベンゾチアジン誘導体を含む抗炎症剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191029 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200122 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200303 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200317 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6678685 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |